MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 6, 2007; DOI: 10.1124/mol.106.031773


0026-895X/07/7106-1572-1581$20.00
Mol Pharmacol 71:1572-1581, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.031773v1
71/6/1572    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jurgens, C. W. D.
Right arrow Articles by Doze, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jurgens, C. W. D.
Right arrow Articles by Doze, V. A.

{alpha}2A Adrenergic Receptor Activation Inhibits Epileptiform Activity in the Rat Hippocampal CA3 Region

Chris W. D. Jurgens, Hana M. Hammad1, Jessica A. Lichter, Sarah J. Boese, Brian W. Nelson, Brianna L. Goldenstein, Kylie L. Davis, Ke Xu, Kristin L. Hillman, James E. Porter, and Van A. Doze

Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota

Norepinephrine has potent antiepileptic properties, the pharmacology of which is unclear. Under conditions in which GABAergic inhibition is blocked, norepinephrine reduces hippocampal cornu ammonis 3 (CA3) epileptiform activity through {alpha}2 adrenergic receptor (AR) activation on pyramidal cells. In this study, we investigated which {alpha}2AR subtype(s) mediates this effect. First, {alpha}2AR genomic expression patterns of 25 rat CA3 pyramidal cells were determined using real-time single-cell reverse transcription-polymerase chain reaction, demonstrating that 12 cells expressed {alpha}2AAR transcript; 3 of the 12 cells additionally expressed mRNA for {alpha}2CAR subtype and no cells possessing {alpha}2BAR mRNA. Hippocampal CA3 epileptiform activity was then examined using field potential recordings in brain slices. The selective {alpha}AR agonist 6-fluoronorepinephrine caused a reduction of CA3 epileptiform activity, as measured by decreased frequency of spontaneous epileptiform bursts. In the presence of betaAR blockade, concentration-response curves for AR agonists suggest that an {alpha}2AR mediates this response, as the rank order of potency was 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK-14304) ≥ epinephrine >6-fluoronorepinephrine > norepinephrine >>> phenylephrine. Finally, equilibrium dissociation constants (Kb) of selective {alpha}AR antagonists were functionally determined to confirm the specific {alpha}2AR subtype inhibiting CA3 epileptiform activity. Apparent Kb values calculated for atipamezole (1.7 nM), MK-912 (4.8 nM), BRL-44408 (15 nM), yohimbine (63 nM), ARC-239 (540 nM), prazosin (4900 nM), and terazosin (5000 nM) correlated best with affinities previously determined for the {alpha}2AAR subtype (r = 0.99, slope = 1.0). These results suggest that, under conditions of impaired GABAergic inhibition, activation of {alpha}2AARs is primarily responsible for the antiepileptic actions of norepinephrine in the rat hippocampal CA3 region.


Received for publication October 13, 2006.

Accepted for publication March 6, 2007.

Address correspondence to: Van A. Doze, Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, 501 North Columbia Road, Stop 9037, Grand Forks, ND 58202-9037. E-mail: vdoze{at}medicine.nodak.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
B. L. Goldenstein, B. W. Nelson, K. Xu, E. J. Luger, J. A. Pribula, J. M. Wald, L. A. O'Shea, D. Weinshenker, R. A. Charbeneau, X. Huang, et al.
Regulator of G Protein Signaling Protein Suppression of G{alpha}o Protein-Mediated {alpha}2A Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity
Mol. Pharmacol., May 1, 2009; 75(5): 1222 - 1230.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics